Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

7TReImHo

Financiado

Cerrado

7kDa TSLP as a novel type of anti inflammatory agent to re establish immune home...

7kDa TSLP as a novel type of anti inflammatory agent to re establish immune homeostasis Intestinal homeostasis is a complex event that relies on different interactions between the host and the commensal flora, also called microbiota. The microbiota is a source of gene products that are required for several functions... ver más

30/06/2014

ISTITUTO EUROPEO D...

164K€

Presupuesto del proyecto: 164K€

Líder del proyecto

ISTITUTO EUROPEO DI ONCOLOGIA SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-06-30 No tenemos la información de la convocatoria

0% 90% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

ISTITUTO EUROPEO DI ONCOLOGI...

0.00€ | Lider

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DENDROWORLD Mucosal dendritic cells in intestinal homeostasis and bacter... 1M€ Cerrado

GUT DCS IN IBD Intestinal dendritic cells and gut T cell homing in inflamma... 181K€ Cerrado

Tbet ILC JFN The role of innate lymphoid cells in regulating intestinal i... 183K€ Cerrado

PID2019-104218RB-I00 MIGRACION Y DIFERENCIACION DE LAS SUBPOBLACIONES DE CELULAS... 139K€ Cerrado

BFU2012-35999 PAPEL DE LAS CELULAS EPITELIALES INTESTINALES Y SUS PROGENIT... 94K€ Cerrado

BFU2008-02683 NUEVOS MEDIADORES DE LA RESPUESTA T EFECTORA Y POTENCIAL TER... 121K€ Cerrado

Líder del proyecto

ISTITUTO EUROPEO DI ONCOLOGIA SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 164K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Intestinal homeostasis is a complex event that relies on different interactions between the host and the commensal flora, also called microbiota. The microbiota is a source of gene products that are required for several functions linked to digestion and energy harvest, thus it has to be tolerated, but at the same time controlled. We have shown that the capacity to tolerate the microbiota is linked to a close interaction between epithelial cells, that are the first line of defence against luminal microorganisms, and specialized immune cells called dendritic cells, that acquire a tolerogenic phenotype and drive the development of T regulatory cells, capable to control the development of inflammatory responses to bacteria. We have identified several effectors mediating this control and focused on a cytokine called thymic stromal lymphopoietin (TSLP) that is released constitutively by epithelial cells and is strongly downregulated in inflammatory bowel disease (IBD). By contrast, in other inflammatory disorders like allergy or asthma, TSLP has been shown to be upregulated and to mediate disease. This apparent controversy is solved when considering that TSLP comes in two different isoforms: a short (sTSLP) and a long (lTSLP). sTSLP has been completely neglected in the literature as most of the reagents do not distinguish it from lTSLP. Within the ERC project Dendroworld, we have generated all the tools to study the function of these two isoforms. We discovered that in IBD there is an inverse correlation between sTSLP and lTSLP. lTSLP is drastically upregulated by recruited immune cells, while sTSLP is downregulated in epithelial cells. Hence, we hypothesized and confirmed that the two isoforms had different activities, with the sTSLP being anti-inflammatory and lTSLP being inflammatory. In this POC we propose scientific and commercialization activities to bring sTSLP to the market as a new class of anti-inflammatory drugs capable of re-establishing immune homeostasis.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores